General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Last updated April 27, 2023
Status:
Concluded with an LOI
Manufacturer:
Alnylam Netherlands B.V.
Indication:
Acute Hepatic Porphyria
Last updated April 27, 2023
Firdapse (amifampridine phosphate)
Status:
Concluded with an LOI
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
Lambert-Eaton Myasthenic Syndrome (LEMS)
Last updated April 25, 2023
Status:
Concluded without agreement
Manufacturer:
Duchesnay Inc.
Indication:
Dyspareunia and/or Vaginal Dryness
Last updated April 14, 2023
Status:
Concluded without agreement
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Postmenopausal vulvovaginal atrophy
Last updated April 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Diabetic Macular Edema
Last updated April 11, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Atopic dermatitis
Last updated April 4, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Medullary thyroid cancer (MTC), rearranged during transfection (RET)-mutant, in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease
Last updated March 31, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Differentiated thyroid carcinoma (DTC), Rearranged during transfection (RET) fusion-positive, in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) monotherapy treatment following prior treatment with sorafenib and/or lenvatinib
Last updated March 31, 2023
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), Monotherapy for the treatment of adult patients
Last updated March 31, 2023